Axogen, Inc. (AXGN): who owns it and who trades it
As of Nov 16, 2026, AXGN insiders reported 34 open-market sales worth $17.1M and no purchases in the last 12 months, with 27% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marc A Began (Vice president), with $3.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Axogen
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AXGN
253 funds and institutions reported AXGN shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.42M | 8.31% | $204M | +14% |
| First Light Asset Management, LLC | 2.75M | 5.17% | $127M | -31% |
| Morgan Stanley | 2.75M | 5.17% | $127M | -12% |
| California State Teachers Retirement System | 2.66M | 5.00% | $57.6M | +4400% |
| Vanguard Capital Management LLC | 2.26M | 4.25% | $104M | -1% |
| Assenagon Asset Management S.A. | 2.09M | 3.93% | $96.4M | +51% |
| Polar Capital Holdings Plc | 1.50M | 2.82% | $69.3M | No change |
| Artemis Investment Management LLP | 1.40M | 2.63% | $64.5M | +299% |
| Wellington Management Group LLP | 1.39M | 2.62% | $64.3M | +44% |
| Geode Capital Management, LLC | 1.38M | 2.59% | $63.5M | +13% |
| Citadel Advisors LLC | 1.36M | 2.56% | $62.9M | +455% |
| Wasatch Advisors LP | 1.30M | 2.44% | $59.9M | -30% |
| Goldman Sachs Group Inc | 1.26M | 2.37% | $58.3M | +116% |
| State Street Corp | 1.25M | 2.34% | $57.6M | +9% |
| FMR LLC (Fidelity) | 1.22M | 2.30% | $56.5M | -7% |
| Hood River Capital Management LLC | 1.07M | 2.01% | $49.3M | – |
| T. Rowe Price Associates | 1.02M | 1.91% | $47M | +1905% |
| Rtw Investments, LP | 1.01M | 1.90% | $46.7M | – |
| Next Century Growth Investors LLC | 872,546 | 1.64% | $40.3M | +1% |
| UBS Group AG | 836,209 | 1.57% | $38.6M | +632% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AXGN insiders reported $0 of open-market purchases and $17.1M of sales. 27% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Joseph A. Tyndall | Director | Sale plan | 3,500 | $49.70 | $174K | Form 4 |
| Aug 11, 2026 | Amy McBride Wendell | Director | Sale plan | 13,353 | $48.42 | $647K | Form 4 |
| Aug 10, 2026 | Marc A Began | Vice president | Sale plan | 67,500 | $47.35 | $3.2M | Form 4 |
| Aug 7, 2026 | Kathy Johnson Weiler | Director | Sale plan | 14,150 | $45.30 | $641K | Form 4 |
| May 8, 2026 | Amy McBride Wendell | Director | Sale | 1,647 | $42.60 | $70.2K | Form 4 |
| May 7, 2026 | John Johnson | Director | Sale | 11,050 | $43.26 | $478K | Form 4 |
| May 7, 2026 | Kathy Johnson Weiler | Director | Sale | 16,344 | $44.09 | $721K | Form 4 |
| May 7, 2026 | Jens Kemp | Chief Marketing Officer | Sale | 4,000 | $43.44 | $174K | Form 4 |
| May 7, 2026 | Lindsey Marie Hartley | CFO | Sale | 478 | $43.67 | $20.9K | Form 4 |
| May 7, 2026 | Lindsey Marie Hartley | CFO | Sale | 573 | $43.67 | $25K | Form 4 |
| May 7, 2026 | Doris Quackenbush | Vice president | Sale | 3,878 | $43.51 | $169K | Form 4 |
| Mar 16, 2026 | Erick Wayne DeVinney | Chief Innovation Officer | Sale | 5,221 | $32.84 | $171K | Form 4 |
| Dec 16, 2025 | Amy McBride Wendell | Director | Sale | 18,248 | $29.31 | $535K | Form 4 |
| Dec 16, 2025 | Amy McBride Wendell | Director | Sale | 5,000 | $29.31 | $147K | Form 4 |
| Dec 16, 2025 | Amy McBride Wendell | Director | Sale | 20,436 | $29.31 | $599K | Form 4 |
| Dec 16, 2025 | Kathy Johnson Weiler | Director | Sale | 6,580 | $29.55 | $194K | Form 4 |
| Dec 16, 2025 | Kathy Johnson Weiler | Director | Sale | 18,248 | $29.55 | $539K | Form 4 |
| Dec 16, 2025 | Kathy Johnson Weiler | Director | Sale | 21,825 | $29.55 | $645K | Form 4 |
| Dec 15, 2025 | Lindsey Marie Hartley | CFO | Sale | 14,812 | $29.86 | $442K | Form 4 |
| Dec 11, 2025 | Marc A Began | Vice president | Sale | 13,222 | $30.00 | $397K | Form 4 |
| Dec 10, 2025 | Michael D Dale | CEO | Sale | 25,000 | $30.00 | $750K | Form 4 |
| Dec 9, 2025 | Michael D Dale | CEO | Sale | 61,463 | $31.21 | $1.9M | Form 4 |
| Dec 9, 2025 | Joseph A. Tyndall | Director | Sale | 10,860 | $30.98 | $336K | Form 4 |
| Dec 9, 2025 | Joseph A. Tyndall | Director | Sale | 14,248 | $30.98 | $441K | Form 4 |
| Dec 9, 2025 | Erick Wayne DeVinney | Chief Innovation Officer | Sale | 19,517 | $31.21 | $609K | Form 4 |
| Dec 9, 2025 | Jens Kemp | Chief Marketing Officer | Sale | 8,156 | $31.21 | $255K | Form 4 |
| Dec 9, 2025 | Marc A Began | Vice president | Sale | 9,278 | $31.21 | $290K | Form 4 |
| Dec 9, 2025 | Paul Thomas | Director | Sale | 21,399 | $29.61 | $634K | Form 4 |
| Dec 9, 2025 | John Johnson | Director | Sale | 8,545 | $29.98 | $256K | Form 4 |
| Dec 9, 2025 | John Johnson | Director | Sale | 13,141 | $29.98 | $394K | Form 4 |
| Dec 8, 2025 | John Johnson | Director | Sale | 11,891 | $31.22 | $371K | Form 4 |
| Dec 8, 2025 | John Johnson | Director | Sale | 11,802 | $31.26 | $369K | Form 4 |
| Dec 8, 2025 | Lindsey Marie Hartley | CFO | Sale | 11,533 | $31.56 | $364K | Form 4 |
| Dec 8, 2025 | Lindsey Marie Hartley | CFO | Sale | 2,854 | $31.56 | $90.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marc A Began | EVP & General Counsel | – | $3.9M | Aug 10, 2026 |
| Kathy Johnson Weiler | Director | – | $2.7M | Aug 7, 2026 |
| Michael D Dale | Chief Executive Officer | – | $2.7M | Dec 10, 2025 |
| Amy McBride Wendell | Director | – | $2M | Aug 11, 2026 |
| John Johnson | Director | – | $1.9M | May 7, 2026 |
| Joseph A. Tyndall | Director | – | $952K | Sep 2, 2026 |
| Lindsey Marie Hartley | CFO | – | $942K | May 7, 2026 |
| Erick Wayne DeVinney | Chief Innovation Officer | – | $781K | Mar 16, 2026 |
| Paul Thomas | Director | – | $634K | Dec 9, 2025 |
| Jens Kemp | Chief Marketing Officer | – | $428K | May 7, 2026 |
| Doris Quackenbush | Sales VP | – | $169K | May 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AXGN short interest
High short interest. 11.7% of AXGN shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 118%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.99M AXGN shares were sold short, 11.7% of the shares outstanding, up 36.5% from the report before. At the average daily volume of 2.13M shares, buying them all back would take about 3.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.99M | 11.71% | +36% | 2.13M | 3.3 |
| Oct 15, 2026 | 5.12M | 9.53% | +9% | 1.69M | 3.0 |
| Sep 30, 2026 | 4.70M | 8.74% | +16% | 1.13M | 4.2 |
| Sep 15, 2026 | 4.06M | 7.54% | +6% | 1.42M | 2.9 |
| Aug 31, 2026 | 3.81M | 7.09% | +13% | 903,167 | 4.2 |
| Aug 14, 2026 | 3.37M | 6.26% | -17% | 826,554 | 4.1 |
| Jul 31, 2026 | 4.07M | 7.57% | -25% | 1.22M | 3.4 |
| Jul 15, 2026 | 5.44M | 10.24% | +17% | 1.50M | 3.6 |
| Jun 30, 2026 | 4.63M | 8.72% | +27% | 1.63M | 2.9 |
| Jun 15, 2026 | 3.66M | 6.89% | +9% | 1.22M | 3.0 |
| May 29, 2026 | 3.37M | 6.34% | +5% | 811,549 | 4.2 |
| May 15, 2026 | 3.20M | 6.02% | -6% | 786,698 | 4.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Axogen company events
Axogen filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Oct 28, 2026ResultsReleased financial results. Filing
- Oct 1, 2026AnnouncementShared information with investors. Filing
- Sep 10, 2026AgreementAmended an earlier report. Of the Original Form 8-K as Exhibit 2.1 and (ii) furnish a corrected version of the investor presentation previously furnished as Exhibit 99.2 to the Original Form 8-K. Except as set forth herein, the Original Form 8-K remains unchanged. Filing
- Sep 10, 2026AgreementAxogen, Inc., a Minnesota corporation, entered into an Agreement and Plan of Merger with Omega Merger Sub, Inc., a Georgia corporation and wholly owned subsidiary of the Company, BioCircuit Technologies, Inc., a Georgia corporation, and Michelle Jarrard, solely as representative of BioCircuit’s… Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- Apr 28, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 23, 2026AgreementAxogen, Inc. entered into an underwriting agreement with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 5, 2025LeadershipThe Compensation Committee of the Board of Directors of Axogen, Inc. approved amendments to the compensation arrangements for Lindsey Hartley, the Company’s Chief Financial Officer. Filing
- Dec 4, 2025AnnouncementThe Company announced it received FDA approval of its Biologics License Application for Avance ® (acellular nerve allograft-arwx). Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Axogen financials
Famous investors that hold AXGN
4 of the 50 well-known investors we track reported holding AXGN in their latest 13F filing. The largest position is Steve Cohen's, worth $16.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 393,903 | $16.5M | 0.0% | +75% |
| Israel Englander · Millennium Management | Q3 2026 | 154,404 | $6.5M | 0.0% | +467% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 30,524 | $1.3M | 0.0% | -98% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 18,831 | $789K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AXGN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Morgan Stanley | 13G/A | 2.8% |
| Nov 13, 2026 | Morgan Stanley | 13G/A | 2.8% |
| Oct 2, 2026 | Divisadero Street Capital Management, LP | 13G | 6.8% |
| Oct 2, 2026 | Divisadero Street Capital Management, LP | 13G | 6.8% |
Questions about Axogen, Inc. (AXGN) stock
Who owns the most AXGN stock?
The largest reported owner of Axogen, Inc. (AXGN) is BlackRock, Inc., with 8.3% of the company. In total, 253 funds and institutions reported holding AXGN at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are AXGN insiders buying or selling?
In the last 12 months, AXGN insiders reported no open-market purchases and 34 sales worth $17.1M. The latest trade was on Sep 2, 2026. See every trade.
What is the short interest in AXGN?
As of Oct 30, 2026, 6.99M AXGN shares were sold short, 11.7% of the shares outstanding, up 36.5% from the report before. At the average daily volume of 2.13M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.
Which famous investors hold AXGN?
4 of the 50 well-known investors we track reported AXGN in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $16.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.